Migraines During Pregnancy: Safe Treatment Options

Pregnancy changes migraine in ways that are not always predictable and not always welcome. Some women experience their best months of migraine management during pregnancy, with attacks nearly disappearing during the second and third trimesters. Others find that the first trimester is the most difficult period they have encountered, with frequent attacks and limited treatment options coinciding with nausea and fatigue that compound the misery. And some experience no change at all.

What does not change during pregnancy is the underlying neurological susceptibility to migraine. What changes dramatically is the treatment landscape. Most of the medications commonly used to manage migraine either carry fetal risk, have insufficient safety data, or are explicitly contraindicated in pregnancy. Navigating migraine management during pregnancy requires understanding what the evidence actually says about safety rather than defaulting to complete avoidance of all treatment.

How Pregnancy Affects Migraine

The effect of pregnancy on migraine is primarily mediated by estrogen. During the first trimester, estrogen levels rise rapidly but erratically, and this hormonal volatility is associated with worsening migraine in many women. The second trimester brings sustained, elevated estrogen levels that stabilize the hormonal environment and, for most women with hormonally influenced migraine, produce a meaningful improvement in attack frequency. Research has found that sixty to eighty percent of women with migraine without aura experience improvement during the second and third trimesters.

Women with migraine with aura experience less consistent improvement during pregnancy. Some find that aura frequency actually increases during pregnancy, which warrants discussion with a neurologist or obstetrician because of the modestly elevated stroke risk associated with migraine with aura.

The postpartum period is a high-risk window for migraine recurrence and worsening. The precipitous drop in estrogen following delivery, combined with sleep deprivation, physical recovery from childbirth, and the stress of caring for a newborn, creates a convergence of migraine risk factors that frequently drives a significant increase in attack frequency in the weeks and months after delivery.

Non-Pharmacological Management

Because pharmacological options are limited during pregnancy, non-pharmacological approaches take on greater importance.

Maintaining consistent sleep timing is particularly important during pregnancy, when sleep is frequently disrupted by physical discomfort. Regular meal timing to avoid prolonged fasting is relevant during pregnancy, particularly for women who find that blood glucose fluctuations contribute to their attacks. Adequate hydration is important during pregnancy for multiple reasons beyond migraine.

Cold or warm compresses applied to the head and neck during an attack provide symptomatic relief without pharmacological risk. Rest in a dark, quiet environment remains the most universally applicable acute intervention.

Medications Considered Relatively Safe During Pregnancy

Acetaminophen is the analgesic most consistently considered appropriate for use during pregnancy at recommended doses. Some recent research has raised questions about associations between prenatal acetaminophen exposure and neurodevelopmental outcomes in children, and these findings are under ongoing evaluation. Discussing the current evidence with a clinician before using acetaminophen regularly during pregnancy is appropriate.

Metoclopramide and ondansetron are antiemetic medications sometimes used during pregnancy for severe nausea that also have some evidence for use in migraine-associated nausea. Magnesium supplementation, which has evidence for migraine prevention, is also used during pregnancy for other indications including preeclampsia prevention and is generally considered safe.

Medications to Avoid During Pregnancy

Valproate is explicitly contraindicated in pregnancy due to a well-established risk of major congenital malformations and neurodevelopmental harm in exposed children. Women of childbearing potential who are taking valproate for migraine prevention should discuss alternative preventive options with their clinician before becoming pregnant.

Topiramate carries risk of cleft palate and other congenital abnormalities and is generally avoided during pregnancy. The CGRP monoclonal antibodies and gepant class medications have insufficient pregnancy safety data and are not recommended during pregnancy. Ergotamine-containing medications cause uterine contractions and are contraindicated throughout pregnancy.

Triptans occupy a complicated middle position. They are not formally approved for use during pregnancy, and most guidelines recommend avoiding them, particularly during the first trimester. However, the available observational data has not found a clear signal of major fetal harm from first-trimester triptan exposure, and the decision to use or avoid triptans during pregnancy is a risk-benefit discussion that should be conducted individually with a clinician.

Working With a Specialist During Pregnancy

Pregnant women with migraine, particularly those with frequent or severe attacks, benefit from a coordinated approach between their obstetrician and a neurologist or headache specialist familiar with migraine in pregnancy. Treatment decisions involve weighing the risks of untreated migraine, which include dehydration, poor nutritional intake, sleep deprivation, and significant disability, against the risks of specific medications in the context of the individual pregnancy.

This is not a conversation that should happen only when an acute attack strikes. Planning the treatment approach before or early in pregnancy, when there is time for an informed discussion rather than an urgent decision during a severe attack, produces better outcomes for both the pregnant person and the pregnancy.